UNIGE document Scientific Article - Review
previous document  unige:41711  next document
add to browser collection

Chemotherapeutic options in the management of anal cancer

Published in Expert Opinion on Pharmacotherapy. 2004, vol. 5, no. 12, p. 2479-84
Abstract During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery. Since the original contribution by Nigro in 1974, surprisingly few changes have been made to the standard of care in chemotherapy, which still consists of a combination of 5-fluorouracil and mitomycin C. However, many issues have yet to be clarified, such as the potential role of cisplatin as a substitute to mitomycin, as well as treatment-induced toxicity in HIV-positive patients. In this paper, the management of patients with anal cancer is presented, and new chemotherapeutic options are critically reviewed. Finally, the authors' opinion regarding currently unresolved issues in the treatment of these rare neoplasms is expressed.
Keywords Anus Neoplasms/therapyCarcinoma, Squamous Cell/complications/therapyCisplatin/therapeutic useCombined Modality TherapyFluorouracil/therapeutic useHIV Seropositivity/complicationsHumansMitomycin/therapeutic use
PMID: 15571466
Full text
Article (Published version) (95 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Chirurgie viscérale (104)
Groupe Roth Arnaud (oncologie) (285)
(ISO format)
GERVAZ, Pascal et al. Chemotherapeutic options in the management of anal cancer. In: Expert Opinion on Pharmacotherapy, 2004, vol. 5, n° 12, p. 2479-84. doi: 10.1517/14656566.5.12.2479 https://archive-ouverte.unige.ch/unige:41711

347 hits

0 download


Deposited on : 2014-11-12

Export document
Format :
Citation style :